PIERIS PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.72 USD | +1.03% |
|
+1.03% | -19.51% |
| Apr. 19 | Pieris Pharmaceuticals Shares Fall After 1-for-80 Reverse Stock Split Announcement | MT |
| Apr. 03 | North American Morning Briefing : Powell Awaited -2- | DJ |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 144 | 199 | 139.9 | 272.4 | 77.38 | 17.99 |
| Enterprise Value (EV) 1 | 15.93 | 111.1 | 86.45 | 169.5 | 31.32 | -8.375 |
| P/E ratio | -5.28 x | -6.48 x | -3.66 x | -5.32 x | -2.32 x | -0.67 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 4.95 x | 4.3 x | 4.77 x | 8.67 x | 2.99 x | 0.42 x |
| EV / Revenue | 0.55 x | 2.4 x | 2.95 x | 5.4 x | 1.21 x | -0.2 x |
| EV / EBITDA | -0.53 x | -4.19 x | -2.73 x | -3.43 x | -0.77 x | 0.6 x |
| EV / FCF | -4.88 x | -2.89 x | -5.37 x | -91.7 x | -0.8 x | 0.31 x |
| FCF Yield | -20.5% | -34.6% | -18.6% | -1.09% | -125% | 319% |
| Price to Book | 3.61 x | 3.89 x | 4.51 x | 5.38 x | 2.77 x | 0.67 x |
| Nbr of stocks (in thousands) | 677 | 687 | 700 | 901 | 930 | 1,236 |
| Reference price 2 | 212.8 | 289.6 | 200.0 | 302.4 | 83.20 | 14.56 |
| Announcement Date | 3/18/19 | 3/13/20 | 3/31/21 | 3/2/22 | 3/31/23 | 3/29/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 29.1 | 46.28 | 29.32 | 31.42 | 25.9 | 42.81 |
| EBITDA 1 | -30.26 | -26.52 | -31.61 | -49.37 | -40.7 | -13.94 |
| EBIT 1 | -30.83 | -27.16 | -33.92 | -51.83 | -43.47 | -15.84 |
| Operating Margin | -105.94% | -58.68% | -115.68% | -164.97% | -167.84% | -37.01% |
| Earnings before Tax (EBT) 1 | -27.07 | -25.47 | -37.07 | -45.74 | -33.28 | -24.54 |
| Net income 1 | -26.75 | -25.47 | -37.23 | -45.74 | -33.28 | -24.54 |
| Net margin | -91.93% | -55.03% | -126.97% | -145.58% | -128.47% | -57.33% |
| EPS 2 | -40.32 | -44.72 | -54.67 | -56.80 | -35.89 | -21.80 |
| Free Cash Flow 1 | -3.267 | -38.41 | -16.11 | -1.848 | -39.22 | -26.68 |
| FCF margin | -11.23% | -83% | -54.93% | -5.88% | -151.43% | -62.33% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/18/19 | 3/13/20 | 3/31/21 | 3/2/22 | 3/31/23 | 3/29/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 |
|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 4.057 | 8.443 | 10.99 | 3.698 | 5.37 | 5.846 | 1.936 | 20.06 | 19.52 |
| EBITDA | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -19.01 | -11 | -7.457 | -12.33 | -12.17 | -11.52 | -15.51 | 2.063 | -11.81 |
| Operating Margin | -468.62% | -130.27% | -67.86% | -333.42% | -226.59% | -197.04% | -801.19% | 10.29% | -60.49% |
| Earnings before Tax (EBT) | -16.54 | -9.532 | -5.101 | - | -9.736 | - | -13.18 | 3.976 | - |
| Net income 1 | -16.54 | -9.532 | -5.101 | -10.34 | -9.736 | -8.102 | -13.18 | 3.976 | -10.75 |
| Net margin | -407.59% | -112.9% | -46.42% | -279.56% | -181.3% | -138.59% | -680.94% | 19.83% | -55.08% |
| EPS 2 | -19.20 | -10.40 | -5.600 | -11.20 | -10.40 | -8.800 | -14.40 | 4.000 | -8.800 |
| Dividend per Share | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/2/21 | 3/1/22 | 5/11/22 | 8/4/22 | 11/2/22 | 3/29/23 | 5/11/23 | 8/10/23 | 11/14/23 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 128 | 87.9 | 53.5 | 103 | 46.1 | 26.4 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -3.27 | -38.4 | -16.1 | -1.85 | -39.2 | -26.7 |
| ROE (net income / shareholders' equity) | -104% | -55.8% | -90.4% | -112% | -84.6% | -89.8% |
| ROA (Net income/ Total Assets) | -15.7% | -12% | -17.2% | -25.1% | -21.8% | -14.8% |
| Assets 1 | 170.2 | 211.9 | 216.1 | 182.5 | 152.5 | 166.3 |
| Book Value Per Share 2 | 59.00 | 74.40 | 44.30 | 56.20 | 30.00 | 21.60 |
| Cash Flow per Share 2 | 111.0 | 90.20 | 101.0 | 130.0 | 41.50 | 14.10 |
| Capex 1 | 1.7 | 2.46 | 2.73 | 0.95 | 1.04 | 0.17 |
| Capex / Sales | 5.83% | 5.32% | 9.3% | 3.02% | 4.02% | 0.4% |
| Announcement Date | 3/18/19 | 3/13/20 | 3/31/21 | 3/2/22 | 3/31/23 | 3/29/24 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -19.51% | 14.49M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- PIRS Stock
- Financials Pieris Pharmaceuticals, Inc.
